## **Core Concept**
The Hepatitis B vaccine is crucial for preventing Hepatitis B virus (HBV) infection, which can lead to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. The vaccine works by inducing immunity through the production of antibodies against the Hepatitis B surface antigen (HBsAg). Seroconversion, or the development of antibodies, is a key indicator of vaccine efficacy.

## **Why the Correct Answer is Right**
The Hepatitis B vaccine is administered in a series of doses, typically 3-4, depending on the vaccine and the individual's age and health status. The seroconversion rate after completing the full series of the Hepatitis B vaccine is generally high. Specifically, after 3 doses of the Hepatitis B vaccine, the seroconversion rate is approximately **95-99%** in healthy individuals. This means that 95-99% of people who receive the full 3-dose series will develop protective antibodies against Hepatitis B.

## **Why Each Wrong Option is Incorrect**
- **Option A:** A seroconversion rate of less than 90% is too low for a vaccine that is known to be highly effective.
- **Option B:** A rate of 90-94% underestimates the efficacy of the Hepatitis B vaccine.
- **Option D:** A rate of more than 99% might overestimate the vaccine's efficacy in the general population, as there can be slight variations based on factors like age, health status, and vaccine formulation.

## **Clinical Pearl / High-Yield Fact**
A crucial point to remember is that the Hepatitis B vaccine is recommended for all infants at birth, for children and adolescents who did not receive the vaccine at birth, and for adults at risk for HBV infection. Non-response or inadequate response to the vaccine can occur in certain populations, such as those with chronic illnesses, immunocompromised individuals, and dialysis patients. In such cases, additional doses or alternative strategies might be necessary.

## **Correct Answer:** . **95-99%**